-
公开(公告)号：EP3348635A1
公开(公告)日：2018-07-18
申请号：EP16844430.5
申请日：2016-09-08
IPC分类号： C12N15/09 , A61K38/00 , A61P5/10 , A61P19/00 , A61P43/00 , C07K14/765 , C07K19/00 , C12N5/16
CPC分类号： C07K14/765 , A61K38/00 , A61P3/00 , A61P5/06 , A61P43/00 , C07K14/61 , C07K19/00 , C07K2319/00 , C12N5/16 , C12N15/09
摘要： Disclosed are a human serum albumin mutant that can be linked to a physiologically active protein to increase the stability of the protein in the blood, as well as a resulting protein produced by linking with the mutant. The protein produced by linking with the mutant consists of a human serum albumin mutant comprising the amino acid sequence set forth as SEQ ID NO:3 or an amino acid sequence that, in comparison with it, lacks not more than 10 amino acid residues and/or has not more than 10 amino acid residues replaced, with the proviso that the asparagine residue occurring at position 318 and the threonine at position 320 from the N-terminus of the amino acid sequence set forth as SEQ ID NO:3 are preserved and linked by peptide bonds via a single amino acid residue (X) except proline placed between those two amino acid residues, and a physiologically active protein linked to the mutant.
-
公开(公告)号：EP4374913A2
公开(公告)日：2024-05-29
申请号：EP24163473.2
申请日：2016-09-08
IPC分类号： A61P5/06
CPC分类号： A61K38/00 , C07K19/00 , C12N5/16 , C12N15/09 , C07K2319/3120130101 , C07K14/765 , A61P43/00 , A61P3/00 , A61P5/06 , C07K14/61
摘要： Disclosed are a human serum albumin mutant consisting of the amino acid sequence set forth as SEQ ID NO:3, as well as a human serum albumin mutant-linked protein (A) comprising a first polypeptide chain comprising the amino acid sequence of the human serum albumin mutant according to claim 1 and a second polypeptide chain linked thereto comprising the amino acid sequence of another protein (A).
-
公开(公告)号：EP3845644A1
公开(公告)日：2021-07-07
申请号：EP20216964.5
申请日：2016-09-08
IPC分类号： C12N15/09 , A61K38/00 , A61P5/10 , A61P19/00 , A61P43/00 , C07K14/765 , C07K19/00 , C12N5/16 , A61P3/00 , C07K14/61 , A61P5/06
摘要： Disclosed are a human serum albumin mutant that can be linked to a physiologically active protein to increase the stability of the protein in the blood, as well as a resulting protein produced by linking with the mutant. The protein produced by linking with the mutant consists of a human serum albumin mutant comprising the amino acid sequence set forth as SEQ ID NO:3 or an amino acid sequence that, in comparison with it, lacks not more than 10 amino acid residues and/or has not more than 10 amino acid residues replaced, with the proviso that the asparagine residue occurring at position 318 and the threonine at position 320 from the N-terminus of the amino acid sequence set forth as SEQ ID NO:3 are preserved and linked by peptide bonds via a single amino acid residue (X) except proline placed between those two amino acid residues, and a physiologically active protein linked to the mutant.
-
公开(公告)号：EP4374913A3
公开(公告)日：2024-08-14
申请号：EP24163473.2
申请日：2016-09-08
IPC分类号： C12N15/09 , A61K38/00 , A61P5/10 , A61P19/00 , A61P43/00 , C07K14/765 , C07K19/00 , C12N5/16 , A61P3/00 , C07K14/61 , A61P5/06
CPC分类号： A61K38/00 , C07K19/00 , C12N5/16 , C12N15/09 , C07K2319/3120130101 , C07K14/765 , A61P43/00 , A61P3/00 , A61P5/06 , C07K14/61
摘要： Disclosed are a human serum albumin mutant consisting of the amino acid sequence set forth as SEQ ID NO:3, as well as a human serum albumin mutant-linked protein (A) comprising a first polypeptide chain comprising the amino acid sequence of the human serum albumin mutant according to claim 1 and a second polypeptide chain linked thereto comprising the amino acid sequence of another protein (A).
-
公开(公告)号：EP4335459A1
公开(公告)日：2024-03-13
申请号：EP22807516.4
申请日：2022-05-11
IPC分类号： A61K47/68 , A61K9/08 , A61K9/19 , A61K38/46 , A61K39/395 , A61K47/02 , A61K47/04 , A61K47/10 , A61K47/12 , A61K47/18 , A61K47/26 , A61P3/00 , A61P25/00 , C12N15/13 , C12N15/56 , C12N15/62
摘要： Provided is a pharmaceutical composition for treatment of mucopolysaccharidosis type I patients. Here, the patient has a disorder particularly in the central nervous system. A pharmaceutical composition containing, as an active ingredient, a fusion protein of an anti-human transferrin receptor antibody and human α-L-iduronidase is administered to a patient with mucopolysaccharidosis type I by intravenous infusion at a dose of 0.1 to 10 mg/kg body weight. The administration is performed continually for at least 3 months at intervals of 5 days to 21 days. This decomposes dermatan sulfate and heparan sulfate accumulated in the tissues of the patient, particularly in the central nervous system.
-
公开(公告)号：EP3450557A1
公开(公告)日：2019-03-06
申请号：EP18199592.9
申请日：2014-12-24
发明人： SONODA, Hiroyuki , MORIMOTO, Hideto , KOSHIMURA, Yuri , KINOSHITA, Masafumi , TAKAGI, Haruna , YOSHII, Yoshiko
摘要： Disclosed are novel anti transferrin receptor antibody that can pass through the blood-brain barrier, a fusion protein comprising a protein necessary to be brought into function in the central nervous system and the antibody, and method of their production. The fusion protein comprises amino acid sequences of an anti-human transferrin receptor antibody that recognizes an amino acid sequence selected from the group consisting of SEQ ID NOs:1, 2, and 3, and of other protein that is bound thereto on the C- terminal side.
-
7.发明公开NOVEL ANTI-TRANSFERRIN RECEPTOR ANTIBODY THAT PASSES THROUGH BLOOD-BRAIN BARRIER 审中-公开DURCH DIE BLUT-HIRN-SCHRANKE PASSIERENDER，NEUARTIGER ANTI-TRANSFERRIN-REZEPTORANTIKÖRPER
公开(公告)号：EP3088518A1
公开(公告)日：2016-11-02
申请号：EP14873852.9
申请日：2014-12-24
发明人： SONODA, Hiroyuki , MORIMOTO, Hideto , KOSHIMURA, Yuri , KINOSHITA, Masafumi , TAKAGI, Haruna , YOSHII, Yoshiko
CPC分类号： C07K16/2881 , A61K38/00 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/622 , C07K2319/00 , C12N9/16 , C12Y301/06013
摘要： Disclosed are novel anti transferrin receptor antibody that can pass through the blood-brain barrier, a fusion protein comprising a protein necessary to be brought into function in the central nervous system and the antibody, and method of their production. The fusion protein comprises amino acid sequences of an anti-human transferrin receptor antibody that recognizes an amino acid sequence selected from the group consisting of SEQ ID NOs:1, 2, and 3, and of other protein that is bound thereto on the C- terminal side.
摘要翻译： 公开了可以通过血脑屏障的新型抗转铁蛋白受体抗体，包含必需在中枢神经系统和抗体中起作用的蛋白质的融合蛋白及其制备方法。 融合蛋白包含识别选自SEQ ID NO：1,2和3的氨基酸序列的抗人转铁蛋白受体抗体的氨基酸序列，以及结合在其上的其它蛋白质， 终端侧。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.011 秒)
